Is ATHA or QYLD a better dividend investment in 2026?

ATHA currently yields 29.63% with a 5% 5-year dividend growth rate. QYLD yields 11.92% with -2.1% growth. The better choice depends on your goal: ATHA offers higher current income.

What is the dividend yield difference between ATHA and QYLD?

ATHA has a forward dividend yield of 29.63% ($2.00/share annually). QYLD yields 11.92% ($2.04/share annually). The yield gap is 17.71 percentage points.

Home › Compare › ATHA vs QYLD

ATHA vs QYLD: Dividend Comparison 2026

ATHA yields 29.63% · QYLD yields 11.92%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 ATHA wins by $104.2K in total portfolio value

INVESTMENT

TIME HORIZON10 years

ATHA

● Live price

29.63%

Share price

$6.75

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$129.6K

Annual income

$16,960.56

Full ATHA calculator →

QYLD

Global X Nasdaq 100 Covered Call ETF

● Live price

11.92%

Share price

$17.15

Annual div

$2.04

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$25.4K

Annual income

$5,659.31

Full QYLD calculator →

Portfolio growth — ATHA vs QYLD

📍 ATHA pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	ATHA	QYLD
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, ATHA + QYLD cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

ATHA pays

QYLD pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ATHA

Annual income on $10K today (after 15% tax)

$2,518.52/yr

After 10yr DRIP, annual income (after tax)

$14,416.48/yr

QYLD

Annual income on $10K today (after 15% tax)

$1,013.51/yr

After 10yr DRIP, annual income (after tax)

$4,810.41/yr

At 15% tax rate, ATHA beats the other by $9,606.06/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ATHA + QYLD for your $10,000?

ATHA: 50%QYLD: 50%

100% QYLD50/50100% ATHA

Portfolio after 10yr

$77.5K

Annual income

$11,309.94/yr

Blended yield

14.60%

📊

Analyst Conviction Gap

Where Wall Street is split right now

ATHA

Analyst Ratings

Hold

Consensus: Hold

Price Target

$13.33

+97.5% upside vs current

Range: $3.00 — $33.00

Altman Z

-18.3

Piotroski

1/9

QYLD

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ATHA buys

QYLD buys

No recent congressional trades found for ATHA or QYLD in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricATHAQYLD

Forward yield	29.63% ✓	11.92%
Annual dividend / share	$2.00	$2.04 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$129.6K ✓	$25.4K
Annual income after 10y	$16,960.56 ✓	$5,659.31
Total dividends collected	$88.0K ✓	$27.1K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: ATHA vs QYLD ($10,000, DRIP)

Year	ATHA Portfolio	ATHA Income/yr	QYLD Portfolio	QYLD Income/yr	Gap
1← crossover	$13,663	$2,962.96	$10,352	$1,192.36	+$3.3K → ATHA
2	$18,403	$3,783.44	$10,830	$1,347.57	+$7.6K → ATHA
3	$24,454	$4,762.59	$11,460	$1,539.07	+$13.0K → ATHA
4	$32,080	$5,914.49	$12,275	$1,777.84	+$19.8K → ATHA
5	$41,577	$7,251.43	$13,323	$2,078.95	+$28.3K → ATHA
6	$53,271	$8,783.33	$14,667	$2,463.34	+$38.6K → ATHA
7	$67,517	$10,517.46	$16,396	$2,960.57	+$51.1K → ATHA
8	$84,701	$12,458.13	$18,631	$3,612.97	+$66.1K → ATHA
9	$105,237	$14,606.49	$21,548	$4,482.15	+$83.7K → ATHA
10	$129,564	$16,960.56	$25,398	$5,659.31	+$104.2K → ATHA

ATHA vs QYLD: Complete Analysis 2026

ATHA — Stock

Athira Pharma, Inc., a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. The company's lead product candidate is ATH-1017, a blood brain barrier-penetrating, small molecule HGF/MET positive modulator that is in LIFT-AD Phase 3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease. It also develops product candidates, which are in preclinical stage, including ATH-1019 for peripheral nervous system indications; and ATH-1020 for neuropsychiatric conditions. Athira Pharma, Inc. was formerly known as M3 Biotechnology, Inc. and changed its name to Athira Pharma, Inc. in April 2019. The company was incorporated in 2011 and is headquartered in Bothell, Washington.

Full ATHA Calculator →

QYLD — ETF

The Global X Nasdaq 100 Covered Call ETF (QYLD) seeks to provide investment results that correspond generally to the price and yield performance, before fees and expenses, of the Cboe Nasdaq-100 BuyWrite V2 Index.

Full QYLD Calculator →

📬

Get this ATHA vs QYLD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ATHA vs SCHD ATHA vs JEPI ATHA vs O ATHA vs KO ATHA vs MAIN ATHA vs XYLD ATHA vs JEPQ ATHA vs RYLD

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.